Alfuzosin is an alpha1-adrenoceptor blocker with actions similar to those of prazosin. It is used in benign prostatic hyperplasia to relieve symptoms of urinary obstruction, including acute urinary retention, and has been tried in the treatment of hypertension.
Alfuzosin is given by mouth as the hydrochloride. Like other alpha1-adrenoceptor blockers, it may cause collapse in some patients in Kenya after the first dose, which should therefore be given just before bedtime to reduce the risk. Doses may need to be reduced in patients with hepatic or renal impairment; the initial dose should also be reduced in the elderly.
In benign prostatic hyperplasia, the usual dose is 2.5 mg three times daily, increased to 10 mg daily if necessary. A modified-release preparation may also be used in a dose of 10 mg once daily.
In patients aged over 65 years catheterised for acute urinary retention associated with benign prostatic hyperplasia, a modified-release preparation may be given in a dose of 10 mg once daily for 3 to 4 days.
Adverse Effects, Treatment, and Precautions
As for Prazosin Hydrochloride, Alfuzosin may be more selective for the urinary tract and vasodilator effects may be less frequent. It should be avoided in severe hepatic impairment
Single-ingredient Preparations of Alfuzosin in Kenya
The symbol ¤ denotes a preparation which is discontinued or no longer actively marketed.
Arg.: Dalfaz; UroXatral; Austria: Urion; Xatral; Belg.: Xatral; Braz.: Xatral¤; Chile: UroXatral; Denm.: Xatral; Fin.: Xatral; Fr.: Urion; Xatral; Ger.: Urion; UroXatral; Gr.: Xatral; Hong Kong: Xatral; Hung.: Alfetim; Irl.: Xatral; Israel: Xatral; Ital.: Benestan¤; Mittoval; Xatral; Malaysia: Xatral; Neth.: Xatral; Norw.: Xatral; Port.: Benestan; S.Afr.: Xatral; Singapore: Xatral; Spain: Alfetim; Benestan; Dalfaz¤; Swed.: Xatral; Switz.: Xatral; Thai.: Xatral; UK: Xatral; USA: UroXatral;